Researchers spot molecular control switch for preterm lung disorders

by Karen N. Peart
Researchers spot molecular control switch for preterm lung disorders

(Medical Xpress)—Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.

The findings are published online ahead of print in the March issue of American Journal of Respiratory Cell and Molecular Biology.

Bronchopulmonary (BPD) is the most common in and does not have any specific treatment. The disorder affects about 97% of infants with birth weights below 1,250 grams, and can lead to repeated , as well as to emphysema and in adulthood.

A research team led by Dr. Vineet Bhandari, associate professor of pediatric neonatology and obstetrics, gynecology & reproductive sciences at Yale School of Medicine, theorized that if the molecules that cause these disorders can be blocked early on, they could essentially prevent lifelong lung problems.

Bhandari and his team studied the lung tissue of newborn mice. The team noted that when this lung tissue was exposed to hyperoxia —excess oxygen in tissues and organs that activates all components of the stress pathways in the newborn lung— there was a marked increase of cyclooxygenase 2 (Cox2) in the lung's stress pathways. This action resulted in BPD in mice. Once the team used a drug that inhibits Cox2, they were able to reverse BPD in mice.

"This is the first time hyperoxia has been comprehensively shown to be responsible for activating the stress pathway in developing lungs," said Bhandari. "Hyperoxia can induce interferon gamma and disrupt lung development, leading to BPD in mice. Once we used the Cox2 inhibitor Celecoxib, we were able to reverse the effects in the mouse BPD models. The drug, originally indicated to treat pain, protected the lungs from cell death, and was able to prevent destruction of and damage to the developing lung exposed to hyperoxia or excess interferon gamma in room air."

Bandari added that the findings suggest that Cox2 and or CHOP—a molecule important in the stress pathway—are potential new drug targets that can be inhibited to treat or prevent human BPD.

Bhandari said the next step is to conduct pre-clinical studies.

More information: Citation: Am. J. Respir. Cell. Mol. Biol. doi:10.1165/rcmb.2012-0381OC (March 2013)

Related Stories

Reversing smoke-induced damage and disease in the lung

date Oct 13, 2011

By studying mice exposed to tobacco smoke for a period of months, researchers have new insight into how emphysema and chronic obstructive pulmonary disease (COPD) develops. In the October 14th issue of Cell they also report ...

Recommended for you

Organ transplant rejection may not be permanent

date 9 hours ago

Rejection of transplanted organs in hosts that were previously tolerant may not be permanent, report scientists from the University of Chicago. Using a mouse model of cardiac transplantation, they found that immune tolerance ...

Researchers find key mechanism that causes neuropathic pain

date 11 hours ago

Scientists at the University of California, Davis, have identified a key mechanism in neuropathic pain. The discovery could eventually benefit millions of patients with chronic pain from trauma, diabetes, shingles, multiple ...

Deep sea light shines on drug delivery potential

date 11 hours ago

A naturally occurring bioluminescent protein found in deep sea shrimp—which helps the crustacean spit a glowing cloud at predators—has been touted as a game-changer in terms of monitoring the way drugs ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.